EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.
Reina HaraMasaki KanazuAmi IwaiTomoki KugeMikako IshijimaTakeshi UenamiYuki AkazawaYukihiro YanoToshihiko YamaguchiMasahide MoriPublished in: Thoracic cancer (2021)
Here, we report a rare case involving a 66-year-old man with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma and antisynthetase syndrome (ASS) treated with osimertinib. The patient presented with respiratory failure and bilateral pulmonary opacities; he was diagnosed with ASS accompanied by interstitial lung disease (ILD), consistent with paraneoplastic syndrome. After steroid pulse therapy, osimertinib was administered for lung adenocarcinoma without ILD exacerbation. Osimertinib could therefore be a treatment option for EGFR-mutant lung cancer with paraneoplastic ILD.
Keyphrases
- epidermal growth factor receptor
- interstitial lung disease
- systemic sclerosis
- advanced non small cell lung cancer
- tyrosine kinase
- case report
- small cell lung cancer
- respiratory failure
- rheumatoid arthritis
- rare case
- idiopathic pulmonary fibrosis
- wild type
- extracorporeal membrane oxygenation
- chronic obstructive pulmonary disease
- pulmonary hypertension
- mechanical ventilation
- intensive care unit
- acute respiratory distress syndrome
- replacement therapy